🧪 Beta — BiohacksAI is under active development. Data and features may change.
B
BiohacksAI
Evidence-Based Biohacking
BetaPatent Pending

HIPK3

MOLECULAR TARGET

homeodomain interacting protein kinase 3

UniProt: Q9H422NCBI Gene: 1011428 compounds

HIPK3 (homeodomain interacting protein kinase 3) is targeted by 28 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HIPK3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2foretinib4.3476
3ruxolitinib4.2368
4pi 1034.1764
5bosutinib4.0858
6bi 25364.0154
7quizartinib3.9953
8midostaurin3.8546
9silmitasertib3.7843
10nintedanib3.6136
11bms 3870323.4731
12tae 6843.4330
13fedratinib3.4029
14linifanib3.3327
15dovitinib3.0921
16lestaurtinib3.0420
17ruboxistaurin2.9418
18defosbarasertib2.8917
19r 4062.8316
20pha 6657522.7114
21plx 47202.7114
22kw 24492.6413
23gsk 6906932.6413
24ast 4872.5612
25su 0148132.208
26sel 120 free base1.956
27Sorafenib1.614
28pictilisib0.691

About HIPK3 as a Drug Target

HIPK3 (homeodomain interacting protein kinase 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 28 compounds with documented HIPK3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HIPK3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.